Transactions disclosed
Avalo Therapeutics Inc NASDAQ:AVTX Chief Medical Officer Mittie Doyle sold 25,492 shares of common stock on March 16, 2026, for a total proceeds of $411,606. The disposition was executed at a price of $16.1465 per share.
Concurrent option exercises
On the same date, Doyle exercised options to acquire 25,492 shares of Avalo common stock. Those option exercises comprised 19,500 shares at an exercise price of $12.65 per share and 5,992 shares at an exercise price of $8.04 per share, representing a combined exercise value reported as $294,850.
Recent price movement and valuation note
Following the sale, Avalo shares have moved lower to $14.68, a decline of 10% over the past week, according to InvestingPro data. InvestingPro analysis also indicates the shares have risen 98% over the past year and are currently trading above its Fair Value estimate.
Analyst coverage and trial timeline
Several brokerages have recently published views on Avalo. TD Cowen reiterated its Buy rating on the company. Guggenheim initiated coverage with a Buy rating and assigned a $50 price target, citing optimism regarding Avalo's IL-1beta inhibitor AVTX-009 for the treatment of hidradenitis suppurativa. The Guggenheim analyst highlighted attributes of the drug's high-affinity targeting that could enable less frequent dosing compared with competitors.
H.C. Wainwright also maintained a Buy rating with a $25 price target following an investor meeting in which Avalo management discussed the Phase 2 LOTUS trial. Data from that trial are anticipated in the second quarter of 2026.
Bottom line
The CMO's sale and simultaneous option exercises were executed on March 16, 2026, and involved identical share counts for the sale and the exercised options. Market price movement since the transactions and analyst commentary are part of the current public record; InvestingPro flags a valuation premium versus its Fair Value estimate even as brokerages maintain positive ratings.
Key points
- Insider activity: CMO Mittie Doyle sold 25,492 shares on March 16, 2026, for $411,606 at $16.1465 per share and exercised options to obtain the same number of shares.
- Valuation and price action: Shares have fallen to $14.68, down 10% over the past week, while having gained 98% over the past year; InvestingPro suggests the stock is trading above its Fair Value estimate.
- Analyst sentiment and trial timing: TD Cowen reiterated a Buy, Guggenheim initiated coverage with a $50 target citing AVTX-009's potential, and H.C. Wainwright kept a Buy with a $25 target; Phase 2 LOTUS trial data are expected in Q2 2026.
Risks and uncertainties
- Share-price volatility: The stock's 10% decline over the prior week and its doubled value over 12 months indicate potential for significant price swings, affecting equity investors and market participants in the biotech sector.
- Valuation divergence: InvestingPro's Fair Value analysis suggests shares may be overvalued relative to that estimate, presenting valuation risk for investors.
- Clinical-readout timing: Anticipated Phase 2 LOTUS trial data in Q2 2026 introduce a timing-related uncertainty that could influence company valuation and analyst views.